SPEVIGO Boehringer Ingelheim Pty Ltd
Product name
SPEVIGO
Sponsor
Accepted date
Nov-2024
Active ingredients
spesolimab
Proposed indication
SPEVIGO is used to treat and prevent flares of generalised pustular psoriasis in adults and adolescents aged 12 and older.
Application type
C (new indication)
Publication date
Nov-2024